Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75629
UPID:
CREG1_HUMAN
Alternative names:
Cellular repressor of E1A-stimulated genes 1
Alternative UPACC:
O75629; B2RDD4; Q8N9A3
Background:
Protein CREG1, also known as Cellular repressor of E1A-stimulated genes 1, plays a crucial role in the transcriptional control of cell growth and differentiation. It functions by antagonizing the transcriptional activation and cellular transformation induced by the adenovirus E1A protein. This activity is essential for the regulation of cell growth and requires interaction with IGF2R.
Therapeutic significance:
Understanding the role of Protein CREG1 could open doors to potential therapeutic strategies. Its involvement in the transcriptional control of cell growth and differentiation highlights its potential as a target for developing treatments aimed at regulating cell proliferation and transformation.